Literature DB >> 8329571

Three-stage chromogenic assay for the analysis of activation properties of factor X by cancer procoagulant.

W P Mielicki1, S G Gordon.   

Abstract

The cysteine proteinase, cancer procoagulant (CP; EC 3.4.22.26) was isolated from human amnion-chorion and purified by precipitation with polyethylene glycol and either ion exchange or immunoaffinity chromatography. A new, sensitive, three-stage chromogenic assay was developed for determination of CP factor X-activating activity. Using this assay some properties including dose-response, effect of calcium, phospholipid and pH on the activation of factor X by CP was determined. There was an excellent linear correlation (r2 = 0.99) between concentration and the enzymatic activity of CP. The activation of factor X by purified CP was calcium dependent with an optimum calcium concentration of 7 mM. CP was not phospholipid dependent. There was a rather broad pH optimum between pH 6.9 and 7.25 for the activation of factor X by CP.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8329571     DOI: 10.1097/00001721-199306000-00008

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  7 in total

1.  Lupus anticoagulant, warfarin, and alternative laboratory monitoring of anticoagulation.

Authors:  Siva S Ketha; Rajiv K Pruthi; Robert D McBane; Waldemar E Wysokinski
Journal:  J Thromb Thrombolysis       Date:  2014-05       Impact factor: 2.300

Review 2.  The hypercoagulable state of malignancy: pathogenesis and current debate.

Authors:  Graham J Caine; Paul S Stonelake; Gregory Y H Lip; Sean T Kehoe
Journal:  Neoplasia       Date:  2002 Nov-Dec       Impact factor: 5.715

Review 3.  Pathogenesis of thrombosis in patients with malignancy.

Authors:  A Falanga; M B Donati
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

4.  Rat prostate tumors express cancer procoagulant, an activator of coagulation factor X.

Authors:  Malgorzata Kamocka; Morris Pollard; Mark Suckow; Wojciech P Mielicki; Elliot D Rosen
Journal:  Comp Med       Date:  2008-06       Impact factor: 0.982

5.  In Vitro Screening of Synthetic Fluorogenic Substrates for Detection of Cancer Procoagulant Activity.

Authors:  Jason Krause; Carminita L Frost
Journal:  Protein J       Date:  2018-04       Impact factor: 2.371

6.  The proteolytic profile of human cancer procoagulant suggests that it promotes cancer metastasis at the level of activation rather than degradation.

Authors:  Nalise Low Ah Kee; Jason Krause; Gregory L Blatch; Koji Muramoto; Kazuo Sakka; Makiko Sakka; Ryno J Naudé; Leona Wagner; Raik Wolf; Jens-Ulrich Rahfeld; Hans-Ulrich Demuth; Wojciech P Mielicki; Carminita L Frost
Journal:  Protein J       Date:  2015-10       Impact factor: 2.371

7.  Arsenic trioxide downregulates cancer procoagulant activity in MCF-7 and WM-115 cell lines in vitro.

Authors:  Ewelina A Hoffman; Katarzyna Gizelska; Marek Mirowski; Wojciech Mielicki
Journal:  Contemp Oncol (Pozn)       Date:  2015-05-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.